Gilead Sciences on Monday agreed to purchase Kite Pharma for $11.9 million, reports Reuters. Here are four things to know about the deal. 1. Gilead will pay $180 per share for Kite Pharma in an ...

Kite Pharma, a Gilead Company (NASDAQ:GILD), and Daiichi Sankyo Co., Ltd. (OTCPK:DSNKY) jointly announced the revision of their 2017 partnership pact, which gave Daiichi Sankyo exclusive rights to ...

For cell therapy manufacturers such as Kite Pharma where every product is made for a single patient, labeling becomes a ...

Kite Pharma Inc., a cancer drug developer, on Wednesday said that it had raised $20 million in a private placement of preferred stock that included its existing backers and a new investor. The ...

Gilead’s Kite Pharma has tied down a licensing deal for Refuge Biotechnologies’ gene expression platform in hopes of developing new blood cancer treatments and plans to take flight with a new ...

Gilead Sciences has agreed to acquire Kite Pharma for approximately $11.9 billion, the companies said today, in a deal that combines the chimeric antigen receptor T-cell (CAR-T) pipeline of Kite, a ...

With the goal of becoming a powerhouse in oncology, Gilead Sciences is closely tracking the progress of its two marketed CAR-T therapies. Armed with its CAR-T unit Kite Pharma and FDA-approved ...

– Daiichi Sankyo to Transfer Yescarta Marketing Authorization in Japan to Gilead Sciences K.K. – – Kite Cell Therapy Business Unit at Gilead Sciences K.K. Will Manage the Sales and Promotion ...

SANTA MONICA, Calif., Feb. 3, 2015 /PRNewswire/ -- Kite Pharma, Inc., (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) ...